Related Experiment Video
Updated: Dec 18, 2025

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors
Published on: April 5, 2024
Using heparin molecules to manage COVID-2019
Jian Liu1, Jine Li1, Katelyn Arnold1
1Division of Chemical Biology and Medicinal Chemistry Eshelman School of Pharmacy University of North Carolina Chapel Hill North Carolina USA.
Insights
Low-molecular-weight heparin shows promise in reducing mortality for severe COVID-19 patients with coagulopathy. This research explores heparin
Area of Science:
- Virology
- Pharmacology
- Biochemistry
Background:
- The COVID-19 pandemic presents a major global health challenge.
- Effective treatments for SARS-CoV-2 infection are urgently needed.
- Heparin has shown potential in mitigating COVID-19 severity.
Purpose of the Study:
- To investigate the mechanisms by which heparin may reduce SARS-CoV-2 severity.
- To propose a novel therapeutic strategy using "designer" heparin molecules.
Main Methods:
- Review of current clinical evidence on heparin use in COVID-19.
- Hypothesizing potential molecular mechanisms of heparin's action.
- Proposing a synthetic biology approach for creating "designer" heparin.
Main Results:
- Emerging data indicate heparin reduces mortality in severe COVID-19 patients with coagulopathy.
- Heparin-like molecules may offer a viable treatment or preventative strategy for SARS-CoV-2.
- The proposed "designer" heparin could offer a targeted therapeutic approach.
Conclusions:
- Heparin demonstrates potential in managing severe COVID-19, particularly in patients with clotting issues.
- Further research into heparin's mechanisms and synthetic derivatives is warranted.
- Synthetic biology offers a novel pathway for developing advanced heparin-based therapeutics against SARS-CoV-2.
Abstract:
The coronavirus disease 2019 (COVID-19) pandemic is becoming one of the largest global public health crises in modern history. The race for an effective drug to prevent or treat the infection is the highest priority among health care providers, government officials, and the pharmaceutical industry. Recent evidence reports that the use of low-molecular-weight heparin reduces mortality in patients with severe coronavirus with coagulopathy. Although the full scope of the benefits from heparin for COVID-19 patients is unfolding, encouraging clinical data suggest that heparin-like molecules may represent a useful approach to treat or prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The intent of this article is to offer our opinions on the mechanism(s) by which heparin may attenuate the course of SARS-CoV-2 infection. Furthermore, we propose a novel strategy to treat or prevent SARS-CoV-2 infection using "designer" heparin molecules that are fabricated using a synthetic biology approach.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

